BRPI0716549A2 - moduladores de quinase associada de interleucina-1 - Google Patents

moduladores de quinase associada de interleucina-1

Info

Publication number
BRPI0716549A2
BRPI0716549A2 BRPI0716549-8A2A BRPI0716549A BRPI0716549A2 BR PI0716549 A2 BRPI0716549 A2 BR PI0716549A2 BR PI0716549 A BRPI0716549 A BR PI0716549A BR PI0716549 A2 BRPI0716549 A2 BR PI0716549A2
Authority
BR
Brazil
Prior art keywords
interleukin
associated kinase
kinase modulators
modulators
kinase
Prior art date
Application number
BRPI0716549-8A2A
Other languages
English (en)
Inventor
Kevin Guckian
Charles Jewell
Patrick Conlan
Edward Yin-Shiang Lin
Timothy Chan
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0716549A2 publication Critical patent/BRPI0716549A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0716549-8A2A 2006-09-07 2007-09-07 moduladores de quinase associada de interleucina-1 BRPI0716549A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84280106P 2006-09-07 2006-09-07
PCT/US2007/019588 WO2008030584A2 (en) 2006-09-07 2007-09-07 Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase

Publications (1)

Publication Number Publication Date
BRPI0716549A2 true BRPI0716549A2 (pt) 2013-09-24

Family

ID=39157878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716549-8A2A BRPI0716549A2 (pt) 2006-09-07 2007-09-07 moduladores de quinase associada de interleucina-1

Country Status (15)

Country Link
US (1) US8293923B2 (pt)
EP (1) EP2061786A2 (pt)
JP (1) JP2010502717A (pt)
KR (1) KR20090049076A (pt)
CN (1) CN101616910A (pt)
AU (1) AU2007292929A1 (pt)
BR (1) BRPI0716549A2 (pt)
CA (1) CA2663100A1 (pt)
IL (1) IL197274A0 (pt)
MX (1) MX2009002377A (pt)
NO (1) NO20091326L (pt)
NZ (1) NZ575410A (pt)
RU (1) RU2459821C2 (pt)
WO (1) WO2008030584A2 (pt)
ZA (1) ZA200901529B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2243481A1 (en) * 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
HUE037860T2 (hu) 2010-11-19 2018-09-28 Ligand Pharm Inc Heterociklusos aminok és alkalmazásuk
EP2858500A4 (en) * 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
EP2903617B1 (en) 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
RU2660435C2 (ru) * 2013-02-07 2018-07-06 Мерк Патент Гмбх Макроциклические производные пиридазинона
HUE032863T2 (en) * 2013-02-07 2017-11-28 Merck Patent Gmbh Piridazinonamid derivatives
WO2015006181A1 (en) 2013-07-11 2015-01-15 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015983A2 (pt) * 2014-01-10 2017-08-08 Aurigene Discovery Tech Ltd Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
SMT202400142T1 (it) * 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
KR20170016500A (ko) * 2014-06-20 2017-02-13 오리진 디스커버리 테크놀로지스 리미티드 Irak4 저해제로서의 치환된 인다졸 화합물
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Irak4抑制劑組合
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な2−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10501437B2 (en) 2016-04-29 2019-12-10 Bayer Pharma Aktiengesellschaft Crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
HUE064389T2 (hu) 2016-04-29 2024-03-28 Bayer Pharma AG Az N-{6-(2-hidroxipropán-2-il)-2-[2-(metilszulfonil)etil]-2h-indazol-5-il}-6- (trifluormetil)piridin-2-karboxamid polimorf formája
UA124237C2 (uk) 2016-06-01 2021-08-11 Байєр Енімал Хелс Гмбх Заміщені індазоли, придатні для лікування і попередження алергійних і/або запальних захворювань у тварин
CN106222183B (zh) * 2016-07-25 2019-11-08 南通大学 靶向人irak1基因的小干扰rna及其应用
TWI733982B (zh) 2017-02-16 2021-07-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
MX2020003666A (es) 2017-10-31 2020-08-03 Curis Inc Compuestos y composiciones para el tratamiento de trastornos hematologicos.
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
WO2020263967A1 (en) * 2019-06-27 2020-12-30 Biogen Ma Inc. 2h-indazole derivatives and their use in the treatment of disease
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
CN115710253B (zh) * 2021-08-23 2024-07-02 上海交通大学 一类含有氨基苯并咪唑类衍生物及其制备和用途
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716111D0 (en) * 1987-07-08 1987-08-12 Unilever Plc Edible plastic dispersion
ID21698A (id) * 1996-11-15 1999-07-15 Darwin Discovery Ltd Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
AU6870098A (en) * 1997-03-31 1998-10-22 Du Pont Merck Pharmaceutical Company, The Indazoles of cyclic ureas useful as hiv protease inhibitors
KR100718830B1 (ko) * 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
ES2367422T3 (es) * 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer

Also Published As

Publication number Publication date
CN101616910A (zh) 2009-12-30
US8293923B2 (en) 2012-10-23
IL197274A0 (en) 2009-12-24
JP2010502717A (ja) 2010-01-28
ZA200901529B (en) 2009-11-25
MX2009002377A (es) 2009-03-13
RU2009112598A (ru) 2010-10-20
NO20091326L (no) 2009-04-01
WO2008030584A3 (en) 2008-07-17
EP2061786A2 (en) 2009-05-27
US20110152260A1 (en) 2011-06-23
CA2663100A1 (en) 2008-03-13
NZ575410A (en) 2012-03-30
RU2459821C2 (ru) 2012-08-27
KR20090049076A (ko) 2009-05-15
WO2008030584A2 (en) 2008-03-13
AU2007292929A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
BRPI0717035A2 (pt) Moduladores de benzotriazol cinase
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
EP2089308A4 (en) DONOR
DE602006004717D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE112007002915A5 (de) Verstelleinrichtung
DE602007003893D1 (de) Kippambossanordnung
AT504580A3 (de) Scan-einrichtung
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602007001280D1 (de) Getränkeextraktor
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE502007001629D1 (de) Rfahren
DE602006020192D1 (de) Riemenscheibenanorndung
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007001098D1 (de) Spindelmäheinheit
DE602007004080D1 (de) Tintenstrahlaufnehmer
EP1841794A4 (en) MODULATORS ADAM-9
DE502007000361D1 (de) Stanznieteinheit
DE602007000333D1 (de) Napfbefestigungsvorrichtung
DE602006019150D1 (de) Riemenscheibenanorndung
DE112007003147A5 (de) Rohr-Biegevorrichtung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.